Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
doi:10.1016/j.ceb.2011.08.004 105
Qiu, Y., Huang, J
The proportions of adolescents with a PGI-C response of moderately improved or much improved ranged from 45% to 61% in the 30mg ritlecitinib groups at week 24 vs 10% to 22% in placebo groups.22 Pediatric patients In pediatric patients, a recent phase 1 study characterized the pharmacokinetic and safety parameters of ritlecitinib in patients with AA aged 6 to 0.05)
Why Should Research Buyers Review Lot Traceability
Zabihi, T
Cold Spring Harb Perspect Med 1, a009316 (2011)
US$ 23.52
US$ 20.09
US$ 21.29
US$ 24.38
